Clinical Trial Update: An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. [Phase 2]

View source ↗

Summary

Phase II open-label, single-arm multicenter study evaluating amivantamab in combination with FOLFIRI as second-line treatment for RAS/BRAF wild-type advanced co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: Yonsei University | Conditions: RAS/BRAF Wild-type Advanced Colorectal Cancer Patients | Phase 2 | Status: NOT_YET_RECRUITING